drugset / Trial / NCT02629536

Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.

NCT02629536

Phase 3 Unknown 90 enrolled University of Notre Dame Australia
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Migraine affects 15% of Western Australians and is a leading cause of suffering and disability in our community (1,2). Research suggests that inflammation of the brain's coverings (meninges) by nerve cell inflammation and the release of 'free radicals', is a cause of migraine. N-acetylcysteine, Vitamin E and Vitamin C are powerful anti-oxidants (free-radical scavengers) that reduce brain inflammation and nerve activity. It is therefore possible these anti-oxidants could reduce the number and severity of migraines. We will study 90 subjects to see if a combination of N-acetylcysteine 600 mg, Vitamin E 250 IU and vitamin C 500 mg (NEC) taken twice daily for 3 months, will reduce migraine attacks. This safe vitamin-based therapy has never been studied and if effective, will play an important role in migraine prevention.

Timeline

Start
2016-03
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg
Subject Vitamin C Other / unclassified 500 mg
Subject Vitamin E Other / unclassified 250 iu

Indications